Clinical Research in Solid Tumors (CREST)

Ernest Nadal / Josep M. Piulats

PRINCIPAL INVESTIGATORS
  • Margarita Garcia Martin
  • Berta Laquente Saez
  • Mariona Calvo Campos
  • Maria Del Carmen Galan Guzman
  • Ramon Palmero Sanchez
  • Maria Jové Casulleras
CLINICAL RESEARCHERS
  • Francesc Torrent Llagostera
  • Veronica De Michele
  • Noelia Vilariño Quintela
  • Mar Marín Melià
POSTDOCTORAL RESEARCHERS (R2)
  • Elisabeth Aliagas Marín
  • Mireia Gausachs Romero
PREDOCTORAL RESEARCHERS (R1)
  • Valentin Navarro Perez
SCIENTIFIC SUPPORT
  • Maite Encuentra Marti
  • Xavi Pérez Martín
  • Marina Figuerola Sans
MANAGEMENT SUPPORT
  • Lluïsa Carbonell Mirabent
  • Carles Codony Servat
  • Iqra Jabeen
Cancer
Oncobell

Scientific production

41

PAPERS

Impact factor: 325,649

16 PUBLICATIONS IN FIRST DECILE

25 PUBLICATIONS IN FIRST QUARTILE

Selected publications

  • Antonarakis, Emmanuel S.; Piulats, Josep M.; Gross-Goupil, Marine; Goh, Jeffrey; Ojamaa, Kristiina; Hoimes, Christopher J.; Vaishampayan, Ulka; Berger, Ranaan; Sezer, Ahmet; Alanko, Tuomo; de Wit, Ronald; Li, Chunde; Omlin, Aurelius; Procopio, Giuseppe; Fukasawa, Satoshi; Tabata, Ken-ichi; Park, Se Hoon; Feyerabend, Susan; Drake, Charles G.; Wu, Haiyan; Qiu, Ping; Kim, Jeri; Poehlein, Christian; de Bono, Johann Sebastian. Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. JOURNAL OF CLINICAL ONCOLOGY. 10.1200/JCO.19.01638
  • Grob JJ; Gonzalez R; Basset-Seguin N; Vornicova O; Schachter J; Joshi A; Meyer N; Grange F; Piulats JM; Bauman JR; Zhang P; Gumuscu B; Swaby RF; Hughes BGM. Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629). JOURNAL OF CLINICAL ONCOLOGY. 10.1200/jco.19.03054
  • Ruiz de Porras V; Wang XC; Palomero L; Marin-Aguilera M; Solé-Blanch C; Indacochea A; Jimenez N; Bystrup S; Bakht M; Conteduca V; Piulats JM; Buisan O; Suarez JF; Pardo JC; Castro E; Olmos D; Beltran H; Mellado B; Martinez-Balibrea E; Font A; Aytes A. Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment. EUROPEAN UROLOGY. 10.1016/j.eururo.2020.10.001
  • Pros, E.; Saigi, M.; Alburquerque-Bejar, J. J.; Catala, I; Palmero, R.; Jove, M.; Lazaro, C.; Verdura, S.; Teule, A.; Sanchez-Cespedes, M.. Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors. ANNALS OF ONCOLOGY. 10.1016/j.annonc.2019.09.001
  • Esteve-Puig R; Climent F; Piñeyro D; Domingo-Domenech E; Davalos V; Encuentra M; Rea A; Espejo-Herrera N; Soler M; Lopez M; Ortiz-Barahona V; Tapia G; Navarro JT; Cid J; Farre L; Villanueva A; Casanova I; Mangues R; Santamarina-Ojeda P; Fernández AF; Fraga MF; Piris MA; Kol N; Avrahami C; Moshitch-Moskkovitz S; Rechavi G; Sureda A; Esteller M. Epigenetic Loss of m1A RNA Demethylase ALKBH3 in Hodgkin Lymphoma Targets Collagen Conferring Poor Clinical Outcome. BLOOD. 10.1182/blood.2020005823

Research highlights

PROJECTS

7 Ongoing projects
3 granted projects 

 

159 Ongoing clinical trials
26 Started clinical trials

Selected projects

  • Phase II stUdy of ALoCelyvir in patientS with mEtastatic Uveal Melanoma (PULSE-UM) (2020 – 2023) PI: PIULATS RODRIGUEZ, JOSEP MARIA. Funder: FIS-Instituto de Salud Carlos III.
  • A phase IA/B open-label, dose-escalation study of the safety and pharacokinetics of MTIG7192A as a single agent and incombination with atezolizumab in patients with locally advanced or metastatic tumors (2017 – 2026) PI: GIL MARTIN, MARTA. Funder: Genentech, Inc.
  • A single arm, open-abel, multicenter, multinational, safety and efficacy phase IIIB trial of BI 695502 plus MFOLFOX6 in patients with previously untreated metastatic colorectal cancer (2017 – 2021) PI: SANTOS VIVAS, CRISTINA. Funder: BOEHRINGER INGELHEIM INTERNATIONAL GmbH.
  • Ensayo clínico abierto, randomizado, multicéntrico fase 1B/3 de talimogene laherparepvec en combinación con pembrolizumab para el tratamiento de pacientes con carcinoma de células escamosas de cabeza y cuello metastásico o recurrente (2016 – 2020) PI: MESIA NIN, RICARD. Funder : Amgen, Inc.
  • Estudio fase 3 aleatorizado de la combinación de PEMBROLIZUMAB (MK-3475) más epacadostat (INCB024360) solos o con quimioterapia a base de plantino en comparación con pembrolizumab más quimioterapia a base de platino más placebo como tratamiento de primera línea en pacientes con cáncer de pulmón no mmicrocítico metastásicoo (2018 – 2024) PI: NADAL ALFORJA, ERNEST. Funder ref.: MK-3475-715.